GenSci094 + Placebo RecFSH / follitropin alfa + Biological: RecFSH / Follitropin alfa (Days 1 to 7) + Placebo GenSci094 + RecFSH / Follitropin alfa (Days 8 to hCG) + Ganirelix + hCG + Progesterone

Phase 3Completed
0 views this week 0 watching Active
Interest: 40/100
40
Hype Score

Development Stage

Pre-clinical
Phase 1
Phase 2
4
Phase 3
5
Approved
Indication / Disease

Infertility

Conditions

Infertility

Trial Timeline

Mar 24, 2023 → Jan 29, 2024

About GenSci094 + Placebo RecFSH / follitropin alfa + Biological: RecFSH / Follitropin alfa (Days 1 to 7) + Placebo GenSci094 + RecFSH / Follitropin alfa (Days 8 to hCG) + Ganirelix + hCG + Progesterone

GenSci094 + Placebo RecFSH / follitropin alfa + Biological: RecFSH / Follitropin alfa (Days 1 to 7) + Placebo GenSci094 + RecFSH / Follitropin alfa (Days 8 to hCG) + Ganirelix + hCG + Progesterone is a phase 3 stage product being developed by Sun Pharmaceutical for Infertility. The current trial status is completed. This product is registered under clinical trial identifier NCT06091436. Target conditions include Infertility.

What happened to similar drugs?

16 of 20 similar drugs in Infertility were approved

Approved (16) Terminated (4) Active (4)

Hype Score Breakdown

Clinical
17
Activity
8
Company
15
Novelty
0
Community
0

Clinical Trials (1)

NCT IDPhaseStatus
NCT06091436Phase 3Completed